New cancer clinical trial: HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer

Published on: January 01, 2018 at 10:00AM
Conditions:   Breast Cancer;   Breast Cancer Female;   Breast Cancer, Male;   Invasive Breast Cancer;   HER2-positive Breast Cancer;   HER2 Positive Breast Carcinoma;   Stage II Breast Cancer;   Stage III Breast Cancer
Interventions:   Biological: Dendritic Cell Vaccine (DC1);   Drug: Neoadjuvant Chemotherapy;   Procedure: Curative Surgery
Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
Not yet recruiting
http://ift.tt/2qgYSyf